Minerva Neurosciences | NERV - Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
Acadia Pharmaceuticals USD 1.31B 58.54M 2026-06
Adma Biologics USD 408.21M 17.88M 2026-06
ALKERMES USD 1.81B 57.02M 2026-06
Alterity Therapeutics Limited AUD 36.21M 18.58M 2025-12
AstraZeneca USD 50.3B 2.96B 2026-06
BioCryst Pharmaceuticals USD -454.29M 99.55M 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Cipla INR 344.32B 15.13B 2026-03
Clal Biotechnology ILS 121.41M 4.62M 2023-12
Compugen USD 95.35M 7.38M 2026-03
CSL USD 18.66B 2.75B 2025-12
Eli Lilly USD 33.88B 2.68B 2026-06
GlaxoSmithKline GBP 17.64B 223M 2026-06
Grifols EUR 6.21B 133.12M 2025-12
Halozyme Therapeutics USD 143.54M 76.09M 2026-06
Ionis Pharmaceuticals USD 439.74M 51.68M 2026-06
J&J USD 84.97B 3.78B 2026-06
Merck USD 41.93B 3.94B 2026-06
Minerva Neurosciences USD -140.75M 106.17M 2025-12
Neurocrine Biosciences USD 3.69B 286.2M 2026-06
Novartis USD 41.95B 3.02B 2026-06
Novavax USD -190.71M 45.94M 2026-06
Pfizer USD 85.19B 4.91B 2026-06
Roche Holding CHF 32.69B 1.11B 2026-06
Sanofi EUR 69.57B 3.24B 2026-06
Takeda JPY 7.56T 215.7B 2026-06
Vanda Pharmaceuticals USD 327.19M 138.81M 2025-12